© 2005 European Society for Medical Oncology
Invited Paper |
Therapy of breast cancer with molecular targeting agents
Division of Medical Oncology, S. Filippo Neri Hospital, Rome, Italy
* Correspondence to: Prof. Giampietro Gasparini, Unità Operativa Complessa di Oncologia Medica; Azienda Complesso Ospedaliero di Rilevanza Nazionale S. Filippo Neri, via G. Martinotti 20,00135 Rome, Italy; Tel: +39-06-33062237; Fax: +39-06-33062445; Email: gasparini.oncology{at}tiscalinet.it
Invasive breast cancer is a heterogeneous disease sustained by intercorrelated and complex growth pathways. Classically, human breast carcinoma has been classified for therapeutic purposes in two distinct categories: one hormone-correlated, the other hormone-uncorrelated. However, the recent advancements of the technology applied to molecular biology by genomic and proteomic analyses have suggested that many more factors are involved in breast cancer growth and progression and that some clusters of these distinguish subgroups of patients at different prognosis. The knowledge of the diversities between tumor and normal tissue of origin is the key to identify novel targets for new selective therapeutic strategies. In fact, the principal goal of molecular-targeted therapy is the suppression of the transformed phenotype minimally affecting normal cells. This review focuses on the molecular targeting compounds directed against the known molecular pathways involved in breast cancer such as: type I growth factors (HER-2/neu; epidermal growth factor receptor [EGFR]), angiogenesis, cyclooxigenase-2 (COX-2) and farnesylation. Presently, trastuzumab is the first agent approved for therapy of HER-2/neu overexpressing tumors. Several other compounds directed against different targets have entered clinical evaluation and the preliminary results are here presented and commented. The major challenges on the clinical development of targeted therapy include the proper selection of patients, the identification of the optimal dosage and schedule of administration, the combinations with conventional treatments and the more appropriate therapeutic strategy.
Key words: targeted therapy, breast cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. Xiong, S. Gharagozlou, I. Vengco, W. Chen, and J. R. Ohlfest Effective CpG Immunotherapy of Breast Carcinoma Prevents but Fails to Eradicate Established Brain Metastasis Clin. Cancer Res., September 1, 2008; 14(17): 5484 - 5493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steinman, J. Wang, P. Bourne, Q. Yang, and P. Tang Expression of Cytokeratin Markers, ER-alpha, PR, HER-2/neu, and EGFR in Pure Ductal Carcinoma In Situ (DCIS) and DCIS with Co-existing Invasive Ductal Carcinoma (IDC) of the Breast Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 127 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF]
|
|